Clinical Trials /

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

NCT03813147

Description:

This phase I trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not responded to treatment or high-risk myelodysplastic syndrome that has come back. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, and fludarabine phosphate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and pevonedistat may work better in treating patients with acute myeloid leukemia or myelodysplastic syndrome.

Related Conditions:
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
  • Official Title: A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome

Clinical Trial IDs

  • ORG STUDY ID: NCI-2019-00215
  • SECONDARY ID: NCI-2019-00215
  • SECONDARY ID: ADVL1712
  • SECONDARY ID: ADVL1712
  • NCT ID: NCT03813147

Conditions

  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells
  • Recurrent Acute Myeloid Leukemia
  • Recurrent High Risk Myelodysplastic Syndrome
  • Refractory Acute Myeloid Leukemia

Interventions

DrugSynonymsArms
Azacitidine5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, VidazaTreatment (cytarabine, azacitidine, pevonedistat, fludarabine)
Cytarabine.beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)
Fludarabine Phosphate2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)
MethotrexateAbitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)
PevonedistatMLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)
Therapeutic HydrocortisoneAeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, hydrocortisone, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, RectoidTreatment (cytarabine, azacitidine, pevonedistat, fludarabine)

Purpose

This phase I trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not responded to treatment or high-risk myelodysplastic syndrome that has come back. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, and fludarabine phosphate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and pevonedistat may work better in treating patients with acute myeloid leukemia or myelodysplastic syndrome.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To evaluate the tolerability and feasibility of a MLN4924 (pevonedistat) and azacitidine
      (pevonedistat [pevo] + azacitidine [aza]) combination added to the standard fludarabine
      phosphate (fludarabine) and cytarabine re-induction for pediatric patients with
      recurrent/refractory acute myeloid leukemia (AML) and relapsed myelodysplastic syndrome
      (MDS).

      II. To define and describe the toxicities of MLN4924 (pevonedistat) when given in combination
      with azacitidine, fludarabine, and cytarabine to pediatric patients with relapsed/refractory
      AML and relapsed MDS.

      III. To characterize the pharmacokinetics of MLN4924 (pevonedistat) in children with
      recurrent or refractory AML and relapsed MDS.

      SECONDARY OBJECTIVES:

      I. To describe the antitumor activity of MLN4924 (pevonedistat) in combination with
      azacitidine, fludarabine, and cytarabine within the confines of a feasibility study.

      EXPLORATORY OBJECTIVES:

      I. To describe the effect of MLN4924 (pevonedistat) administered on this schedule on
      messenger ribonucleic acid (mRNA) transcript levels of genes known to be induced by MLN4924
      (pevonedistat) mediated NEDD8 activating enzyme (NAE) inhibition.

      OUTLINE:

      Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of
      each cycle. Patients then receive azacitidine intravenously (IV) over 10-40 minutes once
      daily (QD) on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine
      phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients
      with central nervous system (CNS)2 or CNS3 receive cytarabine intrathecally or methotrexate
      intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and
      11-34. Cycle continue for 35 days in the absence of disease progression or unacceptable
      toxicity. Patients with stable or greater with non-hematologic toxicities probably or
      definitely related to pevonedistat may receive an additional cycle of treatment.

      After completion of study treatment, patients are followed up for 30 days.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)ExperimentalPatients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 10-40 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycle continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
  • Azacitidine
  • Cytarabine
  • Fludarabine Phosphate
  • Methotrexate
  • Pevonedistat
  • Therapeutic Hydrocortisone

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have had histologic verification of AML at the original diagnosis.
             Patients must have one of the following:

               -  Recurrent disease in >= 1st relapse with >= 5% blasts in the bone marrow (M2/M3)
                  marrow OR immunophenotypic evidence of disease with >= 0.1% blasts detected by
                  flow cytometry, OR evidence of recurrent cytogenetic or molecular abnormalities
                  consistent with relapse, with or without extramedullary disease

               -  Refractory AML is defined as > 5% blasts in the bone marrow (M2/M3) after > 2
                  induction attempts (i.e., 2 cycles of chemotherapy)

               -  Patients with advanced MDS, including MDS that has progressed to AML, and have
                  experienced relapse are eligible

          -  Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
             years of age

          -  Patients must have fully recovered from the acute toxic effects of all prior
             anti-cancer therapy and must meet the following minimum duration from prior
             anti-cancer directed therapy prior to enrollment. If after the required timeframe, the
             numerical eligibility criteria are met, e.g., blood count criteria, the patient is
             considered to have recovered adequately

               -  Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive

                    -  >= 14 days must have elapsed after the completion of other cytotoxic
                       therapy, with the exception of hydroxyurea, for patients not receiving
                       standard maintenance therapy. Additionally, patients must have recovered
                       from all acute toxic effects of prior therapy

                         -  NOTE: Cytoreduction with hydroxyurea must be discontinued >= 24 hours
                            prior to the start of protocol therapy

               -  Anti-cancer agents not known to be myelosuppressive (e.g. not associated with
                  reduced platelet or absolute neutrophil [ANC] counts): >= 7 days after the last
                  dose of agent

               -  Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody,
                  and toxicity related to prior antibody therapy must be recovered to Grade =< 1

               -  Hematopoietic growth factors: >= 14 days after the last dose of a long-acting
                  growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For
                  agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur. The duration of this interval must be discussed with
                  the study chair and the study-assigned research coordinator

               -  Interleukins, interferons and cytokines (other than hematopoietic growth
                  factors): >= 21 days after the completion of interleukins, interferon or
                  cytokines (other than hematopoietic growth factors)

               -  Stem cell Infusions (with or without traumatic brain injury [TBI]):

                    -  Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem
                       cell infusion including donor leukocyte infusion (DLI) or boost infusion: >=
                       84 days after infusion and no evidence of graft versus host disease (GVHD)

                    -  Autologous stem cell infusion including boost infusion: >= 42 days

               -  Cellular Therapy: >= 30 days after the completion of any type of cellular therapy
                  (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)

               -  Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days
                  after local XRT; >= 42 days after TBI, craniospinal XRT or if radiation to >= 50%
                  of the pelvis; >= 42 days if other substantial brain metastases (BM) radiation

               -  Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131 iodine
                  [I]-metaiodobenzylguanidine [MIBG]): >= 42 days after systemically administered
                  radiopharmaceutical therapy

               -  Patients must not have received prior exposure to MLN4924 (pevonedistat)

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 60
             ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  1 month to < 6 months; 0.4 (male and female)

               -  6 months to < 1 year; 0.5 (male and female)

               -  1 to < 2 years; 0.6 (male and female)

               -  2 to < 6 years; 0.8 (male and female)

               -  6 to < 10 years; 1 (male and female)

               -  10 to < 13 years; 1.2 (male and female)

               -  13 to < 16 years; 1.5 (male) and 1.4 (female)

               -  >= 16 years ; 1.7 (male) and 1.4 (female)

          -  Bilirubin (sum of conjugated + unconjugated) =< upper limit of normal (ULN) for age

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN. For
             the purpose of this study, the ULN for serum glutamate pyruvate transaminase (SGPT) is
             45 U/L

          -  Shortening fraction of >= 27% by echocardiogram, or

          -  Ejection fraction of >= 50% by echocardiogram or radionuclide angiogram

          -  No ventricular or supraventricular arrhythmia on electrocardiogram (EKG)

          -  Prolonged rate corrected QT (QTc) interval < 500 msec

          -  Pulse oximetry > 94% on room air if there is clinical indication for determination
             (e.g. dyspnea at rest)

          -  International normalized ratio (INR) =< 1.5

          -  All patients and/or their parents or legally authorized representatives must sign a
             written informed consent. Assent, when appropriate, will be obtained according to
             institutional guidelines

        Exclusion Criteria:

          -  Pregnant or breast-feeding women will not be entered on this study due to risks of
             fetal and teratogenic adverse events as seen in animal/human studies, OR because there
             is yet no available information regarding human fetal or teratogenic toxicities.
             Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of
             reproductive potential may not participate unless they have agreed to use 1 highly
             effective and 1 additional effective (barrier) method of contraception at the same
             time for the duration of study therapy and for 4 months after the completion of
             MLN4924 (pevonedistat) administration. True abstinence, when this is in line with the
             preferred and usual lifestyle of the subject, is acceptable. Periodic abstinence
             (e.g., calendar, ovulation, symptothermal, post-ovulation methods), withdrawal,
             spermicides only, and lactational amenorrhea are not acceptable methods of
             contraception

          -  Investigational drugs: Patients who are currently receiving another investigational
             drug are not eligible

          -  Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are
             not eligible (except hydroxyurea, which may be continued until 24 hours prior to start
             of protocol therapy)

          -  Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus
             or other systemic agents to prevent graft-versus-host disease post bone marrow
             transplant are not eligible for this trial. Topical immunosuppressive agents (e.g.
             topical steroids) are allowed. Physiologic replacement of hydrocortisone is allowed

          -  Patients who have received drugs that are moderate to strong inducers of CYP3A4 within
             14 days prior to study enrollment are not eligible. Strong inducers of CYP3A4 are not
             permitted during the study

          -  Patients with known hepatitis B surface antigen seropositive or known or suspected
             active hepatitis C infection are not eligible. NOTE: Patients who have isolated
             positive hepatitis B core antibody (i.e. in the setting of negative hepatitis B
             surface antigen and negative hepatitis B surface antibody) must have an undetectable
             hepatitis B viral load. Patients who have positive hepatitis C antibody may be
             included if they have an undetectable hepatitis C viral load

          -  Patients with known hepatic cirrhosis or severe pre-existing hepatic impairment are
             not eligible

          -  Patients with uncontrolled high blood pressure (i.e., >= 99% for age) are not eligible

          -  Patients with any of the following diagnoses:

               -  Acute promyelocytic leukemia

               -  Down syndrome

               -  Juvenile myelomonocytic leukemia

          -  Patients who have a documented active uncontrolled infection are not eligible

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition as the study agent

          -  Patients with human immunodeficiency virus (HIV) are not eligible unless they meet all
             of the following criteria:

               -  CD4 count > 350 cell/mm^3

               -  Undetectable viral load

               -  Maintained on modern therapeutic regimens utilizing non-CYP-interactive agents

               -  No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic
                  infections

          -  Female patients who intend to donate eggs (ova) during the course of this study or 4
             months after receiving their last dose of study drug(s) are not eligible

          -  Male patients who intend to donate sperm during the course of this study or 4 months
             after receiving their last dose of study drug(s) are not eligible
      
Maximum Eligible Age:21 Years
Minimum Eligible Age:1 Month
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence of adverse events
Time Frame:Up to 35 days (1 cycle)
Safety Issue:
Description:Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary Outcome Measures

Measure:Antitumor activity
Time Frame:Up to 1 year
Safety Issue:
Description:Disease response will be assessed according to criteria for patients with acute myeloid leukemia (AML), and will be reported descriptively.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:National Cancer Institute (NCI)

Last Updated

December 9, 2019